DF003 / Mireca - LARVOL DELTA

Evaluate DF-003 in ex Vivo Assays Using Peripheral Blood Mononuclear Cell From Subjects With ROSAH Syndrome (clinicaltrials.gov) - P=N/A | N=4 | Recruiting | Sponsor: Hospices Civils de Lyon | Trial completion date: Sep 2023 ➔ Jan 2024 | Trial primary completion date: Sep 2023 ➔ Jan 2024

Trial completion date • Trial primary completion date • Inherited Retinal Dystrophy • Pain • CXCL8 • TNFA

Evaluate DF-003 in ex Vivo Assays Using Peripheral Blood Mononuclear Cell From Subjects With ROSAH Syndrome (clinicaltrials.gov) - P=N/A | N=4 | Recruiting | Sponsor: Hospices Civils de Lyon | Not yet recruiting ➔ Recruiting

Enrollment open • Preclinical • Inherited Retinal Dystrophy • Pain • CXCL8 • TNFA

Evaluate DF-003 in ex Vivo Assays Using Peripheral Blood Mononuclear Cell From Subjects With ROSAH Syndrome (clinicaltrials.gov) - P=N/A | N=4 | Not yet recruiting | Sponsor: Hospices Civils de Lyon | Trial completion date: May 2023 ➔ Aug 2023 | Initiation date: May 2022 ➔ Aug 2022 | Trial primary completion date: May 2023 ➔ Aug 2023

Preclinical • Trial completion date • Trial initiation date • Trial primary completion date • Inherited Retinal Dystrophy • Pain • CXCL8 • TNFA

Structural Characterization Study of a Lipid Nanocapsule Formulation Intended for Drug Delivery Applications Using Small-Angle Scattering Techniques. (PubMed, Mol Pharm) - "Furthermore, interestingly, the shell becomes thicker in an order of ∼1 nm in presence of the drug compared to the shell thickness of unloaded LNCs as demonstrated by SAXS data. This can be correlated with the strong association of hydrophilic DF003 with Kolliphor HS 15, a polyethylene glycol-based surfactant that predominantly makes up the shell, resulting in a drug-rich hydrated shell."

Journal

Formulation development and upscaling of lipid nanocapsules as a drug delivery system for a novel cyclic GMP analogue intended for retinal drug delivery. (PubMed, Int J Pharm) - "Lipid nanocapsules (LNCs) were prepared with a novel cyclic GMP analogue, DF003, intended for the treatment of neurodegenerative retinal degenerations...Additionally, the manufacturing process was adapted and assessed for a continuous production of LNCs to leverage it for industrial viability. Overall, these findings reveal the remarkable potential of LNCs as drug delivery vehicles and their possibility for clinical translation."

Journal • CNS Disorders